Comparison of Respiratory Syncytial Virus (RSV)–Specific Antibody Durability in Pregnant/Postpartum Individuals and Older Adults After RSV Vaccination Authors: Alisa Kachikis, Collrane Frivold, Mindy Pike, Jonathan C Reed, Jennifer E Stolarczuk, Kittredge McVey, Erica Clark, Clarice Mauer, Sandra McAteer, Ioana Maria Saidac, Alex Harteloo, Marco Carone, Grace Marshall, Linda O Eckert, Alexander L Greninger, Janet A Englund, Helen Y Chu Published: 2026 ABSTRACT AbstractRespiratory syncytial virus (RSV) vaccination is recommended in pregnancy. Limited data exist regarding antibody (Ab) durability to inform revaccination timing. We conducted prospective cohort studies among pregnant and older adults after first RSV vaccination in 2023–2024. Longitudinal samples from 50 pregnant (36 vaccinated) and 16 vaccinated older adults were collected until 12–15 months after vaccination and tested for RSV binding and neutralizing Ab. Mean Ab levels 12–15 months after vaccination were similar between vaccinated maternal and older adult participants (P = .73), suggesting Ab durability up to 1 year after maternal RSV vaccination. RSV binding and neutralizing Ab titers were strongly correlated (R = .73). In the United States, respiratory syncytial virus (RSV) vaccination is recommended in pregnancy between 32 and 36-weeks’ gestation to prevent RSV disease in infants [1]. While other vaccines (eg, tetanus, diphtheria, acellular pertussis, and influenza) are recommended in every pregnancy [2, 3], few data exist regarding RSV-specific antibody (Ab) durability following maternal vaccination to inform the need for revaccination in subsequent pregnancies. Based in part on extrapolation from adult RSV vaccine data, revaccination in subsequent pregnancies is not recommended in the United States [1]. Instead, the administration of monoclonal Ab is recommended for infants born to mothers with a prior RSV vaccine. Among older adults, RSV vaccine effectiveness is preserved across 2 RSV seasons [4]. This is supported by studies showing that Ab titers remain elevated and are not substantially affected by a repeat dose at 1 year, as well as vaccine effectiveness studies showing effectiveness into the second season among healthy older adults without immunocompromising conditions or cardiovascular disease [5, 6]. This report describes the durability of RSV-specific Ab levels 12–15 months after RSV vaccination in pregnant or postpartum individuals compared with older adults. METHODS Study Design We conducted 2 prospective longitudinal cohort studies enrolling pregnant individuals who received a maternal RSV vaccine (Abrysvo; Pfizer) and older adults after their first RSV vaccine (self-reported by participants: Abrysvo, Arexvy [GlaxoSmithKline], or unknown to participant). After obtaining written informed consent, we collected maternal samples at delivery, older adult samples 1 month after vaccination, and samples from both cohorts at 12–15 months after vaccination. In either cohort, individuals were included in this analysis if they had a known RSV vaccine status and paired samples at specified the time points. The studies received ethics approval by the University of Washington Human Subjects Division. Variables We collected clinical data, including race, ethnicity, and insurance status via chart abstraction from electronic medical records or participant self-report, using the Research Electronic Data Capture system (REDCap; version 15.4.5; 2025) through the University of Washington Institute of Translational Health Sciences. We considered participants as being on potentially immunosuppressing medications if they received long-term systemic corticosteroids, biologics, or other immunosuppressants during our study period. RSV vaccine data were collected through the Washington State Immunization Information System data linked to the electronic medical record (pregnancy cohort) and through validated self-report (older adult cohort) [7]. Ab Assays RSV prefusion F protein (preF) immunoglobulin G levels were measured in blood samples using a commercial electrochemiluminescence immunoassay with plates precoated with RSV preF antigen (Meso Scale Diagnostics) [8]. Samples were also tested with an RSV subtype A microneutralization assay [9] (see Supplement materials for methods). All Ab titers are log10-transformed and reported in log arbitrary units (AU) per milliliter (binding Abs) or log international units per milliliter (neutralizing Abs). Statistical Analysis To characterize temporal Ab titer changes, we used generalized estimating equations with an independence working correlation structure to perform linear regressions of Ab titers (binding or neutralizing, separately) against time in months, stratified by either vaccination status or study cohort. For group-specific and for differences in group-specific rates of change (across cohorts or vaccination statuses, separately), 95% Wald confidence intervals (CI) were constructed using robust standard errors. We used Mann-Whitney U tests to compare Ab titer distributions across vaccinated cohorts at different time points (initial and follow-up, separately). We used Spearman rank correlation coefficients to assess the strength and direction of the monotonic relationship between binding and neutralizing Ab titers. We also performed sensitivity analyses excluding (1) individuals with an increase in Ab titers between time points and (2) neutralizing Ab titers above the upper limit of quantitation. Statistical analyses were performed using R version 4.4.1 in RStudio 2025.05.1+513 (Rstudio). RESULTS All individuals were vaccinated in the 2023–2024 season. We tested samples following vaccination for RSV Ab in 36 individuals vaccinated during pregnancy, 14 individuals not vaccinated during pregnancy, and 16 vaccinated older adults. The mean ages (SD) at delivery were 35.0 (4.2) and 37.1 (2.8) years for vaccinated and unvaccinated pregnant persons, respectively, and the mean age (SD) at vaccination was 72.1 (5.5) years for older adults. Pregnant participants received the RSV vaccine at a mean gestational age (SD) of 33.2 (1.4) weeks and a mean of 5.4 (2.2) weeks before delivery. Vaccinated and unvaccinated participants delivered at median gestational ages of 39.1 (interquartile range, 37.5–39.6) and 39.1 (37.3–40.1) weeks, respectively (Supplementary Table 1). The median binding Ab log titers were 6.16 log AU/mL at delivery in vaccinated maternal participants and 6.18 log AU/mL 1 month after vaccination for older adults. At 12–15 months after vaccination, they were 5.79 and 5.98 log AU/mL, respectively (Figure 1 and Supplementary Figure 1). Among the unvaccinated maternal participants, the median binding Ab log titers were 5.29 log AU/mL at the initial visit and 5.5 log AU/mL at 12–15-month follow-up (Figure 2 and Supplementary Figure 2). Binding and neutralizing Ab titer distributions did not differ significantly between vaccinated maternal and older adult participants, at either the initial or the follow-up time points (P > .05 for all 4 tests). Box plots of respiratory syncytial virus (RSV) prefusion F protein binding antibody titers (A) and neutralizing Ab titers (B), stratified by study group and collection time point. Abbreviation: AU, arbitrary units. Respiratory syncytial virus (RSV) prefusion F immunoglobulin G antibody (Ab) titers over time, including binding Ab stratified by study group among vaccinated participants (A), binding Ab stratified by vaccine status among maternal participants (B), andneutralizing Ab stratified by study group among vaccinated participants (C), and neutralizing Ab stratified by study group among vaccinated participants with titers below the upper limit of detection (D). A, Binding Ab titers in maternal and older adult vaccinated participants (n = 50). B, Binding Ab titers in maternal participants with or without RSV vaccination in pregnancy (n = 50). C, Neutralizing Ab titers in maternal and older adult vaccinated participants (n = 50). D, Neutralizing Ab titers in maternal and older adult vaccinated participants with titers below the upper limit of detection (n = 42). Abbreviation: AU, arbitrary units. Among vaccinated participants, the estimated rates of change in mean binding Ab titers after vaccination were similar, at −0.030 (CI,−.037 to −.024) and −0.026 (−.049 to −.004) log AU/mL per month, respectively in the maternal and older adult groups (P = .73; Supplementary Table 2). For neutralizing Ab titers, the estimated rates of change were also similar, at −0.024 (CI,−.030 to −.018) and −0.025 (−.048 to −.002) log IU/mL per month, respectively, in the maternal and older adult groups (P = .97). In maternal participants, the rates of change in mean binding Ab levels postpartum differed by vaccination status (P < .001; the estimated rate of change for unvaccinated maternal participants was 0.015 (CI, −.0004 to 0.031). Observed binding and neutralizing Ab titers were strongly correlated (R = 0.73; Supplementary Figure 3). In a sensitivity analysis excluding participants with Ab titer increase over time (2 maternal participants and 8 older adults excluded; Supplementary Table 2), the rate of change in mean postvaccination binding Ab titers differed significantly between maternal participants (estimated rate, −0.031 [CI, −.037 to −.024]) and older adults (−0.057 [−.076 to −.038]; P = .01), but the difference was not significant for neutralizing Ab titers (P = .07). As in the primary analysis, rate of postpartum change in mean binding Ab levels differed significantly between vaccinated and unvaccinated maternal participants (P = .002). DISCUSSION In this study comparing RSV Ab in vaccinated pregnant and older adults, we found that Ab titers approximately 1 year after vaccination were similar between both groups. RSV vaccine for pregnancy was approved in 2023, and few data exist on the durability of RSV Abs following maternal vaccine and the need for a second dose with subsequent pregnancies to maximize RSV protection in infants. The current study provides support for the current recommendation and highlights the need for more data regarding maternal Ab durability as well as infant immunity and in larger cohorts. There are few direct comparisons of Ab response and durability between pregnant/postpartum and older adults, although these groups are the main target populations for RSV vaccination. In the comparison of RSV preF binding Ab titers between pregnant/postpartum individuals and older adults, we demonstrated that both populations mounted similar and robust vaccine-induced binding Ab responses to RSV preF protein; we did not detect a statistically significant difference in Ab titers between groups either at the initial visit or after 12–15 months. We also tested samples from vaccinated pregnant women and older adult cohorts for RSV neutralizing Ab titers. Comparing these cohorts, we found slightly different rates of change over time for binding Abs but similar rates for neutralizing Abs. We found binding and neutralizing Ab titers to be strongly correlated. RSV neutralization is considered the primary immunological outcome in clinical trials; however, these assays are expensive and require specialized expertise. In addition, RSV neutralizing Abs are mainly directed against the preF conformation of the RSV F protein. The older adult and maternal vaccines contain preF antigen, and several studies have now shown strong correlations between RSV preF binding assay and RSV neutralization results, arguing for the use of RSV preF binding as an acceptable correlate of RSV neutralization, given its cost-effectiveness and high-throughput characteristics [9–11]. Both pregnancy and aging are associated with increased risk of severe respiratory infections. During pregnancy, increased morbidity with respiratory infections is often associated with physiological changes, including decreased total lung volume and underlying cardiac or pulmonary conditions [12]. In addition, complex immunological adaptations occur, resulting in maternal-placental tolerance to protect the fetus. While maternal influenza infection is associated with adverse maternal and fetal outcomes, the effects of RSV infection in pregnancy are less well studied [12]. Nonetheless, pregnant individuals are able to mount immune responses to diverse vaccines, comparable to those responses in nonpregnant individuals [12]. In the sixth decade of life, the immune system of older adults begins to progress toward immunosenescence, with decreasing ability to control infections and respond to vaccines [13]. This supports the findings of increased clinical disease severity seen with RSV infection in older persons. Overall, we found that vaccinated compared with unvaccinated pregnant/postpartum individuals had higher concentrations of RSV preF Ab at delivery and at 12–15-month follow-up. Of note, studies of coronavirus disease 2019 vaccine have determined that maternal anti-spike Ab and neutralizing titers were higher in individuals with hybrid immunity (history of both infection and vaccination) than in those with either vaccination or infection alone [14], although such data are not well defined following RSV vaccine, in part due to the nearly uniform presence of at least some preexisting RSV-specific Ab in adults from prior exposures. Immunogenicity and/or Ab durability data are currently not available from large clinical trials of the maternal RSV vaccine [15]. Further studies are needed to evaluate RSV Ab characteristics and the durability of vaccine-generated RSV preF Ab among people who did and those who did not receive RSV vaccines during pregnancy to evaluate maternal RSV Ab baseline immunity over time. Our analysis encompasses prospective cohorts of pregnant and older adults who received RSV vaccine, along with maternal controls. The ability to link to the state vaccine registry [7] allowed abstraction of accurate vaccine data for pregnant participants and is a strength of the study. Finally, the evaluation of durability of RSV preF Ab among pregnant/postpartum individuals is a clinically important topic, given the lack of data regarding need for RSV revaccination in subsequent pregnancies. Although our study is unique in reporting on the durability of anti-preF protein in pregnant/postpartum people, we are limited by a small sample size. Studies with more participants are needed to further evaluate vaccine responses and Ab durability in these cohorts. Our analysis describes Ab concentrations changes over 12–15 months, without additional measurements during that time interval. This precludes a more detailed analysis of Ab change over time. We note that published studies have demonstrated seasonal variation in RSV Ab titers; however, we did not account for this in our analysis due to the small numbers of individuals and time points included [11]. We also did not measure interval RSV infection in the 2 cohorts; however, to exclude individuals with potential undetected RSV infection, we performed a sensitivity analysis including only individuals without an increase in RSV Ab titers over time. In addition, we did not evaluate other components of the immune response, including T-cell responses and nonneutralizing or functional antibodies, which may play a differential role in protection in these 2 groups. We did not test for Ab responses to RSV G or N proteins, which may also contribute to protection. We would like to fully evaluate the role of these Abs; however, that is beyond the scope of the current analysis. We note that there are key differences between our cohorts, including a higher risk of exposure to RSV in postpartum individuals by their children and young infants. Further studies are needed to elucidate whether natural RSV infection contributes to higher Ab levels during follow-up among cohorts at higher risk for RSV exposure. Finally, Ab titers measured 1 year after pregnancy do not necessarily translate to higher infant Ab titers, as transplacental Ab transfer is affected by multiple factors, including maternal health conditions and gestational age at delivery. In conclusion, our results show that at 1 year after vaccination the change in vaccine-induced Ab titers per month were similar between maternal and older adult participants. We encourage further studies with large diverse cohorts to assess Ab durability following maternal RSV vaccination. Revaccination against RSV in subsequent pregnancies may be warranted to address postpartum Ab waning for optimal prevention of illness in infants, though the optimal window is not yet defined. Supplementary Material